Terms: = Germ cell tumor AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1
365 results:
1. CD133 significance in glioblastoma development: in silico and in vitro study.
Abdoli Shadbad M; Nejadi Orang F; Baradaran B
Eur J Med Res; 2024 Mar; 29(1):154. PubMed ID: 38448914
[TBL] [Abstract] [Full Text] [Related]
2. Simulated microgravity induces DNA damage concurrent with impairment of DNA repair and activation of cell-type specific DNA damage response in microglial and glioblastoma cells.
Singh R; Jaiswal A; Singh RP
Biochim Biophys Acta Mol Cell Res; 2024 Mar; 1871(3):119679. PubMed ID: 38272357
[TBL] [Abstract] [Full Text] [Related]
3. KRAS is a molecular determinant of platinum responsiveness in glioblastoma.
Zuchegna C; Leone S; Romano A; Porcellini A; Messina S
BMC Cancer; 2024 Jan; 24(1):77. PubMed ID: 38225605
[TBL] [Abstract] [Full Text] [Related]
4. Network pharmacology-based strategy to investigate the effect and mechanism of α-solanine against glioma.
Wang C; Liu X; Guo S
BMC Complement Med Ther; 2023 Oct; 23(1):371. PubMed ID: 37865727
[TBL] [Abstract] [Full Text] [Related]
5. FBXO7 Confers Mesenchymal Properties and Chemoresistance in Glioblastoma by Controlling Rbfox2-Mediated Alternative Splicing.
Li S; Chen Y; Xie Y; Zhan H; Zeng Y; Zeng K; Wang L; Zhan Z; Li C; Zhao L; Chen X; Tan Y; Wang Z; Bu J; Song Y; Deng F; Zhou A
Adv Sci (Weinh); 2023 Nov; 10(33):e2303561. PubMed ID: 37822160
[TBL] [Abstract] [Full Text] [Related]
6. Clinical, Morphologic, and Molecular Features of Benign and Intermediate-grade Melanocytic tumors With Activating Mutations in map2k1.
Fumero-Velázquez M; Hagstrom M; Dhillon S; Geraminejad T; Olivares S; Donati M; Nosek D; Waldenbäck P; Kazakov D; Sheffield BS; Tron VA; Gerami P
Am J Surg Pathol; 2023 Dec; 47(12):1438-1448. PubMed ID: 37773074
[TBL] [Abstract] [Full Text] [Related]
7. Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models.
Dyshlovoy SA; Hauschild J; Venz S; Krisp C; Kolbe K; Zapf S; Heinemann S; Fita KD; Shubina LK; Makarieva TN; Guzii AG; Rohlfing T; Kaune M; Busenbender T; Mair T; Moritz M; Poverennaya EV; Schlüter H; Serdyuk V; Stonik VA; Dierlamm J; Bokemeyer C; Mohme M; Westphal M; Lamszus K; von Amsberg G; Maire CL
Mol Pharm; 2023 Oct; 20(10):4994-5005. PubMed ID: 37733943
[TBL] [Abstract] [Full Text] [Related]
8. Computational biology and in vitro studies for anticipating cancer-related molecular targets of sweet wormwood (Artemisia annua).
Dawood H; Celik I; Ibrahim RS
BMC Complement Med Ther; 2023 Sep; 23(1):312. PubMed ID: 37684586
[TBL] [Abstract] [Full Text] [Related]
9. map2k1-mutated melanocytic tumors have reproducible histopathologic features and share similarities with melanocytic tumors with BRAF V600E mutations.
Alomari AK; Harms PW; Andea AA; Warren SJ
J Cutan Pathol; 2023 Dec; 50(12):1083-1093. PubMed ID: 37565534
[TBL] [Abstract] [Full Text] [Related]
10. Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
Augustyn K; Joseph J; Patel AB; Razmandi A; Ali AN; Tawbi HA
Melanoma Res; 2023 Oct; 33(5):406-416. PubMed ID: 37534686
[TBL] [Abstract] [Full Text] [Related]
11. Protein phosphatase 6 regulates trametinib sensitivity, a mitogen-activated protein kinase kinase (MEK) inhibitor, by regulating mek1/2-ERK1/2 signaling in canine melanoma cells.
Yamamoto M; Fujiwara N
J Vet Med Sci; 2023 Sep; 85(9):977-984. PubMed ID: 37495516
[TBL] [Abstract] [Full Text] [Related]
12. Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response.
Randic T; Magni S; Philippidou D; Margue C; Grzyb K; Preis JR; Wroblewska JP; Nazarov PV; Mittelbronn M; Frauenknecht KBM; Skupin A; Kreis S
Cell Rep; 2023 Jul; 42(7):112696. PubMed ID: 37379213
[TBL] [Abstract] [Full Text] [Related]
13. Quantitative profiling of genes associated with cancer pathways in brain tumors.
Majerčíková Z; Dibdiaková K; Galanda M; Galanda T; Richterová R; Kolarovszki B; Račay P; Hatok J
Klin Onkol; 2023; 36(3):224-233. PubMed ID: 37353350
[TBL] [Abstract] [Full Text] [Related]
14. Computational pharmacology profiling of borapetoside C against melanoma.
Bhattacharya K; Khanal P; Patil VS; Dwivedi PSR; Chanu NR; Chaudhary RK; Deka S; Chakraborty A
J Biomol Struct Dyn; 2024 Apr; 42(6):3233-3248. PubMed ID: 37203884
[TBL] [Abstract] [Full Text] [Related]
15. Trametinib in Patients With
Wisinski KB; Flamand Y; Wilson MA; Luke JJ; Tawbi HA; Hong F; Mitchell EP; Zwiebel JA; Chen H; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Behrens RJ; Pennington KP; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2023 Apr; 7():e2200421. PubMed ID: 37053535
[TBL] [Abstract] [Full Text] [Related]
16. Optically activated mek1/2 inhibitors (Opti-MEKi) as potential antimelanoma agents.
Hao C; Li X; Wang Z; Liu L; He F; Pan Z
Eur J Med Chem; 2023 May; 251():115236. PubMed ID: 36924668
[TBL] [Abstract] [Full Text] [Related]
17. Response and Resistance to Trametinib in map2k1-Mutant Triple-Negative Melanoma.
Krebs FS; Moura B; Missiaglia E; Aedo-Lopez V; Michielin O; Tsantoulis P; Bisig B; Trimech M; Zoete V; Homicsko K
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901951
[TBL] [Abstract] [Full Text] [Related]
18. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and mek1/2.
Wang P; Jia X; Lu B; Huang H; Liu J; Liu X; Wu Q; Hu Y; Li P; Wei H; Liu T; Zhao D; Zhang L; Tian X; Jiang Y; Qiao Y; Nie W; Ma X; Bai R; Peng C; Dong Z; Liu K
Signal Transduct Target Ther; 2023 Mar; 8(1):96. PubMed ID: 36872366
[TBL] [Abstract] [Full Text] [Related]
19. An update on genomic aberrations in Spitz naevi and tumours.
Hagstrom M; Fumero-Velázquez M; Dhillon S; Olivares S; Gerami P
Pathology; 2023 Mar; 55(2):196-205. PubMed ID: 36631338
[TBL] [Abstract] [Full Text] [Related]
20. Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma.
Takano K; Munehira Y; Hatanaka M; Murakami R; Shibata Y; Shida T; Takeuchi K; Takechi S; Tabata T; Shimada T; Kishikawa S; Matsui Y; Ubukata O; Seki T; Kaneta Y
Mol Cancer Ther; 2023 Mar; 22(3):317-332. PubMed ID: 36622773
[TBL] [Abstract] [Full Text] [Related]
[Next]
